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Administrative health-care claims databases offer 
a number of attractive features from which to form
the evidence base for conducting pharmacoeco-
nomic studies. These features include the ready
availability of data, real-world health-care practice
patterns, and potentially large sample sizes and long
follow-up. However the ease of access to retro-
spective data also increase the potential for analytic
mining and spurious ﬁndings, especially in the
absence of prespeciﬁed analytic plans. Hence, I
believe that the publication of the report of the
ISPOR Task Force on Retrospective Databases in
this issue represents an important and timely step
toward ensuring the quality of published pharma-
coeconomic evaluations that use claims data as the
basis for their evidence [1].
The goal of the report of the ISPOR Task Force
on Retrospective Databases is to provide a check-
list that can assist decision makers in evaluating the
quality of published studies that use health-related
retrospective databases. From the perspective of
assessing the quality of pharmacoeconomic studies
that are based on evidence from claims data, I
believe that the checklist will be useful and of value
to decision makers. However, many decision
makers may be surprised at the number of pub-
lished claims based pharmacoeconomic studies that
do not provide sufﬁcient answers to many of the
questions posed in the guide. As a result, the ques-
tion remains what steps can be taken to ensure that
published claims based pharmacoeconomic studies
provide answers to the questions posed in the
Checklist? The following suggest a few ideas for
consideration and debate.
One idea might be for Value in Health as well as
other journals that publish pharmacoeconomic
studies to consider establishing a submission policy
that requires authors of claims-based pharma-
coeconomic study manuscripts to submit a stan-
dardized checklist that answers the questions in the
Report. The checklist could be made available both
to the manuscript reviewer and the journal reader.
For example, JAMA as well as other medical jour-
nals require authors of clinical trial papers to
submit alongside their manuscript a completed
checklist and ﬂow diagram that follows the require-
ments set by the Consolidated Standards of Report-
ing Trials (CONSORT) [2]. Given that the Report’s
checklist currently targets decision makers, the
format and content may need to be reorganized 
and expanded to serve as a standardized checklist
for authors submitting claims-based pharmacoeco-
nomic study papers. ISPOR might consider leading
such an initiative and beginning the dialogue with
other journals that publish pharmacoeconomic
studies.
A second idea may be for Value in Health to
encourage publication of data analysis plans for
pharmacoeconomic studies that test hypotheses and
base their primary evidence on claims data. One of
the most important questions from the Checklist for
the decision maker to answer is whether or not a
data analysis plan was developed prior to initiating
the analysis. The development of a data analysis
plan prior to conducting the analysis represents a
critical step for ensuring a rigorous research design
and increasing the credibility of the published
pharmacoeconomic study results. However, given
the retrospective nature and ready availability of
claims data, it is difﬁcult to ensure that a data analy-
sis plan is developed prior to conducting the initial
analysis of the claims data set. Publication of data
analysis plans for those pharmacoeconomic studies
that test hypotheses using claims data may be one
mechanism to help ensure this. A model for this can
be found in papers on the design of clinical trials
published in the journal Controlled Clinical Trials.
Sullivan et al. [3], for instance, prespeciﬁed as a
design paper in Controlled Clinical Trials their
design and analytic considerations for determin-
ing the cost-effectiveness of early intervention in
asthma for a multinational clinical trial. Their
rationale for publishing this economic evaluation
design paper a priori was to increase the credibility
and acceptability of their results upon completion
of the trial.
A ﬁnal idea might be for Value in Health as well
as other relevant journals to require that critical val-
idation studies be completed and published prior to
or in conjunction with publishing the results of an
inferential, claims-based pharmacoeconomic study.
An example of such a study is validating that the
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target population can be accurately identiﬁed in 
the database [4,5]. Another critical validation study
is establishing that comparator cohorts accurately
represent the pharmacotherapies being compared.
For example, do the comparator cohorts accurately
represent patients who have newly started a drug,
switched to a new therapy, or received combination
therapy? To encourage these types of key validation
studies, Value in Health might consider issuing a
call for papers on validation studies for novel phar-
macotherapies that are likely to be evaluated in
pharmacoeconomic studies that use claims data as
their evidence base. An example of a ﬁeld of phar-
macoeconomic studies that might beneﬁt from this
type of validation work is in the evaluation of
asthma controller therapies. A variety of inferential
pharmacoeconomic studies have been recently pub-
lished on this class of pharmacotherapies. For some
of these studies, however, answers have been sought
to questions that are very similar to those questions
posed in the Report’s Checklist [6,7]. Publication 
of these types of validation studies will not only
answer some of these questions, but may also 
motivate analysts to standardize their analytic
approaches for speciﬁc classes of pharmacothera-
pies. The standardization of analytic approaches for
speciﬁc classes of pharmacotherapies can then facil-
itate replication of analyses across different claims
data sets.
In summary, I believe the report of the ISPOR
Task Force on Retrospective Databases in this issue
will serve as a useful guide for decision makers
assessing the quality of published pharmacoeco-
nomic studies that use claims data as the basis for
their evidence. The Checklist builds on the recom-
mendations and standards previously published in
this journal [8,9]. To ensure that future pharma-
coeconomic study publications meet the standards
of the Checklist, consideration should be given to
what other initiatives might be useful to ensure that
researchers provide answers to the Checklist ques-
tions in or along with their manuscript submissions.
This commentary provides some ideas for thought
and to serve as a starting point. However, given 
the challenges of implementing ideas such as these,
further guidance by a panel such as the ISPOR Task
Force on Retrospective Databases would be needed
to progress.
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